Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon

Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.